Pacific Biosciences Of California (PACB) Profit After Tax (2016 - 2025)
Pacific Biosciences Of California has reported Profit After Tax over the past 16 years, most recently at -$40.4 million for Q4 2025.
- Quarterly results put Profit After Tax at -$40.4 million for Q4 2025, down 1802.7% from a year ago — trailing twelve months through Dec 2025 was -$546.4 million (down 76.34% YoY), and the annual figure for FY2025 was -$546.4 million, down 76.34%.
- Profit After Tax for Q4 2025 was -$40.4 million at Pacific Biosciences Of California, down from -$38.0 million in the prior quarter.
- Over the last five years, Profit After Tax for PACB hit a ceiling of $2.4 million in Q4 2024 and a floor of -$426.1 million in Q1 2025.
- Median Profit After Tax over the past 5 years was -$71.4 million (2022), compared with a mean of -$88.2 million.
- Biggest five-year swings in Profit After Tax: crashed 7028.29% in 2021 and later soared 102.89% in 2024.
- Pacific Biosciences Of California's Profit After Tax stood at -$69.3 million in 2021, then dropped by 21.72% to -$84.4 million in 2022, then rose by 2.8% to -$82.0 million in 2023, then soared by 102.89% to $2.4 million in 2024, then crashed by 1802.7% to -$40.4 million in 2025.
- The last three reported values for Profit After Tax were -$40.4 million (Q4 2025), -$38.0 million (Q3 2025), and -$41.9 million (Q2 2025) per Business Quant data.